Company intelligence / Profile preview
Suzhou Stainwei Biotechnology Co., Ltd.
Suzhou, Jiangsu Sheng, Chinastainwei.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple programs in development, with the highest being Phase 2 trials. Their anti-VEGF monoclonal antibody has shown positive results in Phase 1 trials with no dose-limiting toxicities observed. They also have an anti-PD-1 humanized monoclonal antibody (hAB21) that has completed Phase 1 trials for advanced malignant solid tumors.
- Therapeutic areas
- OncologyEndocrinologyImmunologyHematologyOphthalmologyNeurologyInfectious Diseases
- Modalities
- Monoclonal antibodySmall molecule drugRecombinant geneProtein engineering
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Maimonides Medical Center
Beyond the preview
Go deeper on Suzhou Stainwei Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Stainwei Biotechnology Co., Ltd..